Moderna surfaces as the first partner for Jim Wilson's rare disease nonprofit, donating an mRNA program at no cost
A week after Jim Wilson and Alex Karnal debuted their Tachi Yamada-inspired nonprofit aimed at treating ultra-rare diseases, the partner providing the Institute for Life Changing Medicines with its first pipeline program has emerged from the shadows.
Moderna jumped into the spotlight Tuesday, announcing it had donated an mRNA-based therapy for Crigler-Najjar syndrome free of charge. In a press release, CEO Stéphane Bancel said Moderna would have had to charge a fortune if the company had gone on to develop it for profit given the ultra-rare nature of the disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.